MPWT
VRDN icon

MassMutual Private Wealth & Trust’s Viridian Therapeutics VRDN Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$156 – 2504
2026
Q1 		$156 Buy
+8
New +$238 ﹤0.01% 2340

Other funds holding VRDN

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MassMutual Private Wealth & Trust's VRDN Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 8 shares — an estimated $156 sold.

MassMutual Private Wealth & Trust first reported a position in VRDN in Q1 2026 and held it in 1 quarter. The position peaked at $156 in Q1 2026. 44 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 8 Viridian Therapeutics shares in Q2 2026, an estimated $156.
  • MassMutual Private Wealth & Trust first reported a position in Viridian Therapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Viridian Therapeutics position peaked at $156 in Q1 2026.
  • 44 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.